IP Library › Granted Patent US 12,419,965
Granted Patent B2
US 12,419,965 · App. 17/281,697 · Granted Sep 23, 2025

RNA particles comprising polysarcosine

Inventors: Matthias Barz (Worms, DE); Benjamin Weber (Mainz, DE); Heinrich Haas (Mainz, DE); Philipp Heller (Mainz, DE); Sara Nogueira (Mainz, DE); Anne Schlegel (Mainz, DE)
Assignees: BIONTECH SE; Johannes Gutenberg-Universität Mainz
A61K47/6935A61K47/543A61K47/6911A61K48/0041C12N15/85C12N15/88A61K9/127A61K9/5146A61K47/18A61K47/24A61K47/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,419,965
App. No.
17/281,697
Granted
Sep 23, 2025
Kind
B2
Abstract

The present disclosure relates to RNA particles for delivery of RNA to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration, and compositions comprising such RNA particles. The RNA particles in one embodiment comprise single-stranded RNA such as mRNA which encodes a peptide or protein of interest, such as a pharmaceutically active peptide or protein. The RNA is taken up by cells of a target tissue and the RNA is translated into the encoded peptide or protein, which may exhibit its physiological activity.

Claims (15)

1. A composition comprising a plurality of RNA particles, wherein each particle comprises:

(i) RNA;

and

(ii) a polysarcosine-lipid conjugate comprising about 20 to 34 sarcosine units that are attached to one or more lipids which associate with RNA to form RNA liposomes or lipoplexes, wherein the one or more lipids conjugated to polysarcosine are selected from the group consisting of fatty acids, glycerolipids, glycerophospholipids, sphingolipids, saccharolipids, polyketides, sterol lipids and prenol lipids,

wherein the polydispersity index (PDI) of the plurality of RNA particles is from 0.131 to 0.200, and wherein the Z-average particle size of the plurality of RNA nanoparticles is from 50 to 300 nm.

2. The composition of claim 1 further comprising a cationic or cationically ionizable lipid.

3. The composition of claim 2 , wherein the cationically ionizable lipid is positively charged only at acidic pH and does not remain cationic at physiological pH.

4. The composition of claim 1 , wherein the particles either do not comprise a polyethyleneglycol-lipid conjugate or do not comprise a conjugate of polyethyleneglycol and a lipid-like material.

5. The composition of claim 1 , wherein the RNA is mRNA.

6. The composition of claim 2 , wherein the cationic or cationically ionizable lipid comprises N,N-dimethyl-2,3-dioleyloxy) propylamine (DODMA), N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleoyloxy) propyl)-N,N,N-trimethylammonium chloride (DOTAP), N-(1-(2,3-dioleyloxy) propyl)-N,N,N-trimethylammonium chloride (DOTMA), 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), or a mixture thereof.

7. The composition of claim 1 , wherein the polysarcosine-lipid conjugate is a member selected from the group consisting of a polysarcosine-diacylglycerol conjugate, a polysarcosine-dialkyloxypropyl conjugate, a polysarcosine-phospholipid conjugate, a polysarcosine-ceramide conjugate, and a mixture thereof.

8. The composition of claim 1 , wherein the polysarcosine-conjugate inhibits aggregation of the particles.

9. A method for delivering RNA to cells of a subject, the method comprising administering to a subject a composition of claim 1 .

10. A method for treating or preventing a disease or disorder in a subject, the method comprising administering to a subject a composition of claim 1 , wherein the RNA encodes a therapeutic peptide or protein and wherein delivering the therapeutic peptide or protein to the subject is beneficial in treating or preventing the disease or disorder.

11. The method of claim 10 , wherein the subject is a mammal, or wherein the mammal is a human.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2023
From: HAAS, HEINRICH; HELLER, PHILIPP; NOGUEIRA, SARA; SCHLEGEL, ANNE
To: BIONTECH RNA PHARMACEUTICALS GMBH
Reel/Frame 064436/0781 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2023
From: BARZ, MATTHIAS; WEBER, BENJAMIN
To: JOHANNES GUTENBERG-UNIVERSITAT MAINZ
Reel/Frame 064436/0843 →
MERGER AND CHANGE OF NAME Recorded Sep 20, 2021
From: BIONTECH RNA PHARMACEUTICALS GMBH; BIONTECH SE
To: BIONTECH SE
Reel/Frame 057715/0788 →
Continuity (1)
Related Publication 20220001025A1 · Jan 6, 2022
References Cited (78)
US 5614505A · Gmeiner et al. · 1997 [cited by applicant]
US 5705188A · Junichi et al. · 1998 [cited by applicant]
US 10980875B2 · Pascolo et al. · 2021 [cited by applicant]
US 20060083780A1 · Heyes · 2006 [cited by examiner]
US 20080019908A1 · Akitsu et al. · 2008 [cited by applicant]
US 20110123637A1 · Pascolo et al. · 2011 [cited by applicant]
US 20120258046A1 · Mutzke et al. · 2012 [cited by applicant]
US 20130189351A1 · Geall · 2013 [cited by examiner]
US 20150315541A1 · Bancel · 2015 [cited by examiner]
US 20180318436A1 · Pascolo et al. · 2018 [cited by applicant]
EP 2942348A1 · 2015 [cited by applicant]
WO 2009046739A1 · 2009 [cited by applicant]
WO 2009088401A2 · 2009 [cited by applicant]
WO 2009144230A1 · 2009 [cited by applicant]
WO 2011005799A2 · 2011 [cited by applicant]
WO 2013033438A2 · 2013 [cited by applicant]
WO WO2013185069 · 2013 [cited by applicant]
WO 2016072500A1 · 2016 [cited by applicant]
WO WO2017075531 · 2017 [cited by applicant]
WO WO2017218704 · 2017 [cited by applicant]
WO WO2018078053 · 2018 [cited by applicant]
WO WO2018087753 · 2018 [cited by applicant]
WO WO2020069718 · 2020 [cited by applicant]
WO WO2020070040 · 2020 [cited by applicant]
WO WO2020072605 · 2020 [cited by applicant]
Weber, B.; Seidl, C.; Schwiertz, D.; Scherer, M.; Bleher, S.; Süss, R.; Barz, M. Polysarcosine-Based Lipids: From Lipopolypeptoid Micelles to Stealth-Like Lipids in Langmuir Blodgett Monolayers. Polymers 2016, 8, 427. h… [cited by examiner]
Van Tendeloo, Viggo FI, et al. “Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumo… [cited by examiner]
Huesmann, David, et al. “A head-to-head comparison of poly (sarcosine) and poly (ethylene glycol) in peptidic, amphiphilic block copolymers.” Polymer 67 (2015): 240-248. (Year: 2015). [cited by examiner]
Hsu, Shu-Hao et al. “Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor.” Nanomedicine : nanotechnology, biology, and medicine vol. 9,8 (2013): 1169-80. doi:10.1016/j.nano.201… [cited by examiner]
Weber B, Seidl C, Schwiertz D, Scherer M, Bleher S, Suss R, Barz M. Polysarcosine-Based Lipids: From Lipopolypeptoid Micelles to Stealth-Like Lipids in Langmuir Blodgett Monolayers. Polymers (Basel). Dec. 9, 2016;8(12):… [cited by examiner]
Danaei et al., “Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems” Pharmaceutics 10(57):May 1-17, 2018 (Year: 2018). [cited by examiner]
Diana D. Kang et al. “Engineering LNPs with polysarcosine lipids for mRNA delivery.” Bioactive Materials, vol. 37, 2024, pp. 86-93. (Year: 2024). [cited by examiner]
Alexander Birke, Jun Ling, and Matthias Barz. “Polysarcosine-containing copolymers: Synthesis, characterization, self-assembly, and applications.” Progress in Polymer Science, vol. 81, 2018, pp. 163-208. (Year: 2018). [cited by examiner]
David Huesmann et al. “A head-to-head comparison of poly(sarcosine) and poly(ethylene glycol) in peptidic, amphiphilic block copolymers.” Polymer, vol. 67, 2015, pp. 240-248. (Year: 2015). [cited by examiner]
King Hang Aaron Lau et al. “Surface-Grafted Polysarcosine as a Peptoid Antifouling Polymer Brush.” Langmuir, vol. 28, 2012, pp. 16099-16107. (Year: 2012). [cited by examiner]
Yali Hu et al. “Polysarcosine as an Alternative to PEG for Therapeutic Protein Conjugation.” Bioconjugate Chemistry, vol. 29, 2018, pp. 2232-2238. (Year: 2018). [cited by examiner]
Stefan Bleher et al. “Poly(Sarcosine) Surface Modification Imparts Stealth-Like Properties to Liposomes.” vol. 15, Article 1904716, 2019, pp. 1-10. (Year: 2019). [cited by examiner]
Benjamin Weber et al. “Polysarcosine-Based Lipids: From Lipopolypeptoid Micelles to Stealth-Like Lipids in Langmuir Blodgett Monolayers.” vol. 8, 427, 2016, pp. 1-14. (Year: 2016). [cited by examiner]
Wan et al: “Lipid nanoparticle delivery systems for siRNA-based therapeutics”, Drug Delivery and Translational Research, Springer, Germany, vol. 4, No. 1, Jun. 28, 2013 (Jun. 28, 2013), pp. 74-83. [cited by applicant]
Belikov V. G., “Pharmaceutical Chemistry”. 4th Edition, Moscow 2007, 6 pages; submitted with English translation. [cited by applicant]
Ichiki et al. Gan To Kagaku Ryoho, 1993, 20:2239-2242: Abstract. [cited by applicant]
Kaczmarek, J. C. et al., “Advances in the delivery of RNA therapeutics: from concept to clinical reality”, Genome Medicine, 2017, 9, 60, pp. 2, 4-7. [cited by applicant]
Skold, Cancer Immunother., Aug. 15, 2015, 64: 1461-1473. [cited by applicant]
Kariko et al., “Phosphate-enhanced transfection of cationic lipid-complexed mRNA and plasmid DNA”, Biochimica et Biophysica Acta, 1998, 320-334. [cited by applicant]
Schroeder et al., “Lipid-based nanotherapeutics for siRNA delivery”, Journal of Internal Medicine, 2010, 267(1), 9-21. [cited by applicant]
Holm et al., “Synthesis and Characterization of Stimuli-Responsive Star-Like Polypept(o)ides: Introducing Biodegradable PeptoStars”, Macromolecular Bioscience, 2017, 17(6), 14 pages. [cited by applicant]
Ahern, “Biochemical, Reagent Kits Offer Scientists Good Return on Investment” The Scientist, pp. 20-22, (Jul. 1995). [cited by applicant]
Barh et al., “MicroRNA let-7: an emerging next-generation cancer therapuetic,” Curr. Oncol. 17(1):70-80 (Feb. 2010). [cited by applicant]
Bourquin et al., Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance Cancer Res. 71:5123-33 (2011). [cited by applicant]
Diessner et al., Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab ematansine (T-DM1), Cell Death and Disease 5, e1149 (13 pages) (2014). [cited by applicant]
DeLong et al., “Characterization and performance of nucleic acid nanoparticles combined with protamine and gold” Biomaterials 30(32):6451-59 (Nov. 2009). [cited by applicant]
Jafari et al. “Nonviral Approach for targeted nucleic acid delivery,” Current Medicinal Chemistry 19:197-208 (2012). [cited by applicant]
Kerkmann et al., “Immunostimulatory Properties of CpG-Oligonucleotides Are Enhanced by the Use of Protamine Nanoparticles” Oligonucleotides 16:313-22 (2006). [cited by applicant]
Makowska et al., “Sequential Induction of type I and II Interferons mediates a long-lasting gene induction in the liver in response to a novel toll-like receptor 9 agonist” Joumal of Hepatology 48:743-49 (2013). [cited by applicant]
Mayer et al., “Oligonucleotide-prolamine-albumin nanoparticles: Prolamine sulfate causes drastic size reduction” Journal of Controlled Release, 106(1-2):181-87 (Aug. 2005). [cited by applicant]
Meyer et al., “Synthesis and biological evaluation of a bioresponsive and endosomolytic siRNA—polymer conjugate” Molecular Pharmaceuticals 6(3):752-62 (2009). [cited by applicant]
Nakamura et al., “A Double-modulation Strategy in Cancer Treatment With a Chemotherapeutic Agent and siRNA” Molecular Therapy, 19(11):2040-47 (Nov. 2011). [cited by applicant]
Plasay et al., “Selective cytotoxicity assay in anticancer drug of melittin isolated from bee venom ( [cited by applicant]
Rettig et al., “Particle Size and activation threshold:a new dimension of danger signaling” Blood 115(22):4533-41 (Jun. 2010). [cited by applicant]
Shima et al., “Synergistic Stimulation of Antigen Presenting Cells via TLR by Combining CpG ODN and Poly (y-glutamic acid)-Based Nanoparticles as Vaccine Adjuvants” Bioconjugate Chemistry 24:926-33 (2013). [cited by applicant]
Zhang et al., “Structural Analyses of Toll-like Receptor 7 Reveal Detailed RNA Sequence Specificity and Recognition Mechanism of Agonistic Ligands” Cell Reports 25:3371-81 (Dec. 2018). [cited by applicant]
Zhang et al., “Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier or targeted cancer therapy” Biomaterials 34(33):8459-68 (Nov. 2013). [cited by applicant]
The International Search Report (ISR) for PCT/EP2019/076369; dated Nov. 29, 2019, pp. 1-5. [cited by applicant]
The Written Opinion of the International Searching Authority for PCT/EP2019/076369; dated Nov. 29, 2019, pp. 1-7. [cited by applicant]
The International Search Report (ISR) for PCT/EP2016/075156; dated Jan. 9, 2017, pp. 1-4. [cited by applicant]
The Written Opinion of the International Searching Authority for PCT/EP2016/075156; dated Jan. 9, 2017, pp. 1-7. [cited by applicant]
The International Search Report (ISR) for PCT/EP2016/075146; dated Dec. 13, 2016, pp. 1-4. [cited by applicant]
The Written Opinion of the International Searching Authority for PCT/EP2016/075146; dated Dec. 13, 2016, pp. 1-5. [cited by applicant]
Parvanova et al., “The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination” Vaccine, 29:3832-36 (Apr. 2011). [cited by applicant]
Bleher et al., “Poly(sarcosine) surface modification imparts stealth-like properties to liposomes” Small 15(50): 1904716 (pp. 1-10) (Nov. 2019). [cited by applicant]
Hortz et al., “Cylindrical brush polymers with polysarcosine side chains: a novel biocompatible carrier for biomedical applications” Macromolecules 48(7):2074-86 (Mar. 2015). [cited by applicant]
Klein et al., “Efficient shielding of polyplexes using heterotelechelic polysarcosines” Polymers 10(6):689 (Jun. 2018). [cited by applicant]
Klinker et al., “Secondary-structure-driven self-assembly of reactive polypept(o)tides: controlling size, shape, and function of core cross-linked nanostructures” Angewandte Chemie Int Ed 56(32): 9608-13 (Jul. 2017). [cited by applicant]
Nogueira et al., “Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery” ACS Appl. Nano Materials, 3(11):10614-65 (Nov. 2020). [cited by applicant]
Nogueira et al., “Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery” ACS Appl. Nano Materials, 3(11):10614-65 (Nov. 2020). Supporting Information pp. S1-S13. [cited by applicant]
Ramishetti et al., “A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes” Adv. Materials 32 (12):1906128 (pp. 1-8) (Mar. 2020). [cited by applicant]
Son et al., “Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes” Journal of Controlled Release 322(17):209-16 (Mar. 2020). [cited by applicant]
Danaei et al., “Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems” Pharmaceutics 10(57):1-17 (May 2018). [cited by applicant]